The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
Latest news and blogs
Blog |
Public attitudes on the pharmaceutical industry: will increasing familiarity build confidence?
Blog |
Why the government must urgently raise the NICE cost-effectiveness threshold
News |
The UK risks undervaluing life sciences manufacturing investment
News |
Accelerated review of VPAG concludes without agreement
Best practice guidance: Supporting patient organisations to report industry funding
Transparency is essential when pharmaceutical companies work with patient organisations. This updated guidance is aimed at supporting that transparency.
Guidance for conferences and events in the UK: ABPI Code of Practice requirements
This clarifies the ABPI Code requirements for conferences and events, helps all relevant stakeholders operate in a Code-compliant, professional and ethical manner.
2024 ABPI Code of Practice – new resources
The PMCPA has published new webinars and e-learning to aid understanding of the 2024 ABPI Code of Practice.
Lives Lived Well
From patients and their loved ones to those working within the pharmaceutical industry in the UK, we share a common goal: Lives Lived Well.
Events
Online Workshop on SMC: How to prepare and submit to SMC | 08 - 09 December 2025
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
ABPI Annual Conference 2026
ABPI’s flagship annual conference will be taking place in Central London on 23 April 2026.
Companies granted further extension to VPAG 2026 decision deadline
The ABPI and the government have agreed to a further two-week extension to the deadline by which companies must give notice if they intend to leave the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG).
The UK risks undervaluing life sciences manufacturing investment
The official methods used by the UK government to assess the value of innovative life sciences manufacturing may lead the UK to miss out on strategic investments and the jobs and productivity growth they can bring to all regions across the UK
Key facts and figures for the pharmaceutical industry in the UK
£46.7bn
Turnover [6]
£9bn
investment in UK R&D (more than UKRI’s entire annual budget) [3]
£17.6bn
direct Gross Value Added (GVA) [1]